ArticleTrials2026
Neuroendoscopy-assisted drainage versus burr hole drainage for chronic subdural hematoma (URANUS): study protocol for a multicenter randomized controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07144423 (Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma: A Multicenter Randomized Controlled Trial, URANUS
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic subdural hematoma (CSDH), a highly prevalent neurosurgical condition predominantly affecting the elderly, demonstrates an incidence of 58.1/100,000 person-years in individuals ≥ 65 years, escalating to 127/100,000 among octogenarians. Driven by global demographic aging and anticoagulant utilization, its population-level incidence is projected to reach 17.4/100,000 by 2030. The standard surgical intervention-burr hole craniotomy with intraoperative irrigation and closed subdural drainage implantation-carries a documented recurrence rate of 5-33%, where residual hematoma volume constitutes a well-established independent recurrence predictor. Meta-analysis indicates endoscopically guided drainage may reduce recurrence through optimized hematoma evacuation, though robust clinical validation of its therapeutic benefit remains insufficient.
methodsThis prospective, multicenter, open-label, randomized controlled trial employing blinded endpoint assessment will enroll 770 participants aged 18-90 years with radiologically verified symptomatic CSDH. Eligible patients will be randomized to receive neuroendoscopy-assisted drainage (intervention cohort) or burr hole craniotomy drainage (control cohort), with the primary endpoint defined as the occurrence of recurrent hematoma necessitating reintervention within 3 postoperative months. Secondary outcomes comprise postoperative hematoma volume, thickness, and midline shift; neurological function evaluated using standardized assessment scales; quality-of-life measures quantified via validated instruments; catheter indwelling time for subdural drainage; total hospitalization length of stay; all-cause mortality; and incidence of procedure-associated complications. DISCUSSION: This study aims to validate the efficacy and safety of neuroendoscopy-assisted drainage for reducing recurrence rates and improving clinical outcomes in CSDH patients.
trial registrationClinicalTrials.gov, NCT07144423 . Registered on Aug 27, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.